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Background: Lipopolysaccharide (LPS)-mediated sickness behaviour is known to be a result of increased inflammatory
cytokines in the brain. Inflammatory cytokines have been shown to mediate increases in brain excitation by loss
of GABAA-mediated inhibition through receptor internalization or inactivation. Inflammatory pathways, reactive
oxygen species and stress are also known to increase monoamine oxidase-A (MAO-A) and acetylcholinesterase
(ACh-E) activity. Given that neuromodulator actions on neural circuits largely depend on inhibitory pathways and
are sensitive to alteration in corresponding catalytic enzyme activities, we assessed the impact of systemic LPS on
neuromodulator-mediated shaping of a simple cortical network.
Methods: Extracellular field recordings of evoked postsynaptic potentials in adult mouse somatosensory cortical
slices were used to evaluate effects of a single systemic LPS challenge on neuromodulator function 1 week later.
Neuromodulators were administered transiently as a bolus (100 μl) to the bath perfusate immediately upstream
of the recording site to mimic phasic release of neuromodulators and enable assessment of response temporal
dynamics.
Results: Systemic LPS administration resulted in loss of both spontaneous and evoked inhibition as well as
alterations in the temporal dynamics of neuromodulator effects on a paired-pulse paradigm. The effects on
neuromodulator temporal dynamics were sensitive to the Monoamine oxidase-A (MAO-A) antagonist clorgyline
(for norepinephrine and serotonin) and the ACh-E inhibitor donepezil (for acetylcholine). This is consistent with
significant increases in total MAO and ACh-E activity found in hemi-brain samples from the LPS-treated group,
supporting the notion that systemic LPS administration may lead to longer-lasting changes in inhibitory network
function and enzyme (MAO/ACh-E) activity responsible for reduced neuromodulator actions.
Conclusions: Given the significant role of neuromodulators in behavioural state and cognitive processes, it is
possible that an inflammatory-mediated change in neuromodulator action plays a role in LPS-induced cognitive
effects and could help define the link between infection and neuropsychiatric/degenerative conditions.
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Peripheral lipopolysaccharide (LPS) injection is widely
known to induce sickness behaviour [1-6], mediated pri-
marily via the inflammatory cytokines IL-1β [6], IL-6 [7]
and TNF-α [6]. Transduction of this peripheral response
into the CNS is accomplished via indirect stimulation of
vagal sensory nerve activity [8,9] as well as more direct
effects transduced through endothelial prostaglandin
synthesis [2], activation of macrophage-like cells in the
circumventricular organs, and direct transduction across
the blood brain barrier [10] to activate local microglial
cells [11]. All pathways lead to elevated prostaglandins
and inflammatory cytokines in the brain that are thought
to mediate the various sickness behaviours that include
fever, loss of activity, loss of appetite, impaired cognition,
anxiety and depression [9,12,13]. The systemic inflam-
matory response subsides within 7 days [11], sickness
behaviour by 3 days [13], but CNS inflammation and im-
pact may be long-lasting and potentially involved in neu-
rodegenerative processes. Although cytokines are known
to be responsible for sickness behaviour, the mechanisms
by which they alter brain function are still largely
unknown.
Regulation of CNS inhibition seems to be one mech-
anism by which cytokines alter brain state. Interleukin-6
has been shown to lead to a decrease in the inhibition/
excitation ratio in the rat temporal cortex that was pos-
tulated to contribute to a hyper-excitable state associated
with various neurological or psychiatric conditions [14].
Likewise, TNF-α, implicated in plasticity and synaptic
scaling [15,16], can also decrease the inhibition/excita-
tion ratio via increasing glutamate AMPA receptor inser-
tion and GABAA receptor internalization in central
synapses [17]. Thus, inflammatory cytokines are widely
associated with loss of CNS inhibition.
The enzymes responsible for breakdown/inactivation of
many neuromodulators are sensitive to stress and inflam-
mation. Monoamine oxidase-A (MAO-A; breakdown nor-
epinephrine and serotonin) expression has been widely
shown to increase in response to chronic stress [18], glu-
cocorticoids [19,20] and inflammatory p38 MAPK activity
[21]. Acetylcholinesterase (ACh-E; breakdown acetylcho-
line) expression has been shown to increase in response to
IL-1 [22] and oxidative stress [23,24]. Given the effects of
inflammation on MAO-A and ACh-E, the purpose of this
study was to assess the impact of systemic LPS-mediated
neuroinflammation on neuromodulator regulation of som-
atosensory cortical networks. Results showed that a simple
extracellular field recording paradigm can be used to
measure functional neuromodulator alterations following
an inflammatory event. We show that alterations in
neuromodulator shaping of cortical networks 7 days
following systemic LPS administration involve changes
in MAO-A and ACh-E activity. Given the impact thatneuromodulators have on determining behavioural
state, our results support the notion that inflammatory
changes in neuromodulator action may be involved in




Male C57Bl6 mice were purchased from Charles River
Laboratories (Charles River Laboratories Inc, Quebec,
Canada) and allowed to adjust to new environment for a
minimum of 1 week before experimentation. Mice were
individually housed for 1 week after injection and pro-
vided food and water ad libitum in a colony room main-
tained at 20°C with a 12:12-h light-dark cycle (lights on
at 8 a.m.). Experiments were in accordance with the
guidelines of the Canadian Council on Animal Care and
approved by the University of Saskatchewan Committee
on Animal Care and Supply.
Mice (8 to 10 weeks old) received a single intraperitoneal
injection of either vehicle (0.9% saline) or lipopolysac-
charide (strain 0111:B4, >500,000 endotoxin units/mg;
3 mg/kg). One week following a single injection, ani-
mals were sacrificed for experiments. We chose to
assess neuromodulator effects 1 week after injection when
typical sickness behaviours have subsided to assess longer-
lasting effects that may be linked to neuropsychiatric or
neurodegenerative processes.
Brain slice preparation
The brain was rapidly removed on ice and submersed in
ice-cold artificial cerebral spinal fluid (aCSF) containing
(mM): NaCl 123, KCl 3.5, NaH2PO4 1.2, CaCl2 2,
MgSO4 10, NaHCO3 26, ascorbic acid 0.04, dextrose 10
and kynurenic acid 1. Kynurenic acid and high magne-
sium are used to block glutamatergic-mediated excito-
toxicity. The brain was cut down the midline, and half of
the brain was glued midline face down on a brain chuck
for placement on the vibratome (Leica VT 1200, Leica
Biosystems, Wetzlar, Germany). Three to five 350-μm
thick sagittal slices were obtained through hindlimb/
forelimb somatosensory cortex (Figure 1A). Somatosensory
cortex was chosen as representative for neuromodulator
action on sensory processing. Slices for electrophysiology
were immediately transferred to a recovery chamber at
30°C (1 h; thereafter room temperature) in normal aCSF
containing (mM): NaCl 123, KCl 3.5, NaH2PO4 1.2,
CaCl2 2, MgSO4 2, NaHCO3 26, ascorbic acid 0.04 and
dextrose 10.
Electrophysiology
Extracellular electrophysiological recordings were carried
out on C57Bl6 mouse brain slices at room temperature.
Slices were placed in a perfusion chamber (approximately
Figure 1 Cortical paired-pulse suppression is dependent on inhibitory GABAA activity. (A) Schematic of a sagittal brain slice illustrating the
recording and stimulating electrode placements for the model used in these studies. (B) Representative samples of paired-pulse fPSP recordings
in layer II/III before and after bicuculline addition to the slice perfusate. (C) A time series (recordings every 20 s) representation of the average
ratios of pulse 2 amplitude over pulse 1 amplitude before and during bicuculline addition to the bath perfusate. (D) P2/P1 ratio comparison
before and after bicuculline addition for assessment of evoked inhibition. (E) P1 amplitude comparison before and after bicuculline for assessment
of spontaneous inhibition. For D and E, the average of five responses were obtained from each recording at time points demarcated by grey
shading in C. N = 17 slices from five mice. *P < 0.001, paired t-test. Con, control; bic, bicuculline; P1, pulse 1; P2, pulse 2; aCSF, artificial cerebral
spinal fluid; min, minutes.
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normal aCSF gassed with 5% CO2 and 95% O2 and imaged
using a Nikon SMZ1000 stereozoom microscope (Nikon
Corporation, Chiyoda, Tokyo, Japan) for placement of
recording and stimulating electrodes. Recordings were
obtained with a differential amplifier (DP311; Warner In-
struments, Hamden, CT, USA) connected to a Digidata
1440A (Molecular Devices, Sunnyvale, CA, USA) using
PClamp 10.2 software (Molecular Devices, Sunnyvale, CA,
USA). Signals were captured at 2 kHz, high-pass filtered
at 1 Hz and low-pass filtered at 1 kHz. Recording elec-
trodes (filament thin-wall glass; WPI, Sarasota, FL,
USA) were pulled on a vertical Narishige PC-10 two-
step puller (Narishige, Tokyo, Japan), filled with 0.9%
saline (resistance <4 MΩ) and positioned in layer II/III
of hindlimb somatosensory cortex (Figure 1A). Stimula-
tion (15 to 30 μA; 0.5 ms; 0.33 Hz) was applied to layer
IV/V (Figure 1A) using a concentric bipolar-stimulating
electrode (CBARC75, FHC Inc, Bowdoin, ME, USA)
via a constant current stimulator (Iso-Flex; A.M.P.I.,
Jerusalem, Israel) controlled by PClamp through the
digital output on the Digidata 1440A (Molecular Devices,
Sunnyvale, CA, USA). Only recordings (approximately
60% of max) of maximal postsynaptic potentials (PSP)
greater than 1.2 mV were used in these studies.
Neuromodulators were delivered to the chamber as a
bolus injection (100 μl; Hamilton syringe) directlyupstream (approximately 1 mm) of the recording electrode
through PE-10 tubing (Harvard Apparatus, Holliston, MA,
USA) positioned in the chamber using a bent 16-gauge
needle. Unlike the slow and stable increase in neuro-
modulator concentration seen with addition to the
bath perfusate (tonic release associated with level of
arousal), bolus application resembles more closely the
acute physiological release (phasic release) of neuromo-
dulators associated with environmental stimuli that are
necessary for transient modulation of executive func-
tions. Furthermore, bolus delivery enables evaluation
and comparison of the temporal profiles of neuromo-
dulator actions. Acetylcholine (ACh; 10 and 5 mM),
norepinephrine (NE; 5 and 2 mM) and serotonin
(5-HT; 2 and 1 mM) were dissolved in normal aCSF
and administered via Hamilton syringe. Given the 2-ml
volume of the chamber, a flow rate of approximately
4 ml/min and the necessity of the neuromodulator to
diffuse greater than 100 μm into the tissue slice, we
guestimate the concentration of neuromodulator to
only reach 100 to 1,000-fold lower at the recording site
(<50 μM), which is consistent with prior studies asses-
sing neuromodulator function via perfusion delivery
[25,26]. Clorgyline (5 μM), donepezil (100 nM) and
bicuculline (2 μM) were added to normal aCSF and de-
livered via the bath perfusate (and slice incubation bath
in the case of clorgyline). All chemicals were obtained
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Tail suspension test
Mice were suspended by the tail (tape approximately
2 cm from tip of tail) to a surface 50 cm above the table
and videotaped for 6 min. Individual videos were manu-
ally scored for total immobility time over the 6 min and
latency to first immobility using a stop watch by an
observer blinded to the treatment group [13,27,28].
MAO, ACh-E and NO assays
Total brain monoamine oxidase activity was measured
using the MAO-Glo™ assay kit (Promega, Madison, WI,
USA, Cat.# V1401) that uses a derivative of beetle luciferin
as a luminogenic MAO substrate. Mouse hemi-brain tissue
was homogenized in cold phosphate buffer 0.1 M (pH 8.0;
4 μl/mg tissue) and protein content measured by the Brad-
ford assay (Bio-Rad Laboratories Inc, Hercules, CA, USA).
Brain samples (40 μg protein) were run in triplicates
and added to a reaction mixture containing the 4× MAO
substrate and reaction buffer provided in the kit as
directed. The resulting luminescent signal was read on a
luminometer (SpectraMax® M5 Multi-Mode microplate
reader, Molecular Devices, Sunnyvale, CA, USA) and all
data normalized to the average of the saline-treated group
for direct comparison.
Acetylcholinesterase activity was measured using the
method described by George Ellman and colleagues in
1961 [29]. Mouse hemi-brain tissue was homogenized in
cold phosphate buffer 0.1 M (pH 8.0; 4 μl/mg tissue) and
protein content measured by the Bradford assay (Bio-Rad
Laboratories Inc, Hercules, CA, USA). Brain samples
(20 μg protein) were run in triplicates and added to a reac-
tion mixture containing 300 μl of 0.1 M phosphate buffer
(pH 8.0), 2 μl of the substrate 0.075 M acetylthiocholine
iodide and 10 μl of 0.01 M 5-5 dithiobis (2-nitrobenzoic
acid) (DTNB). Samples were read using a spectrophotom-
eter (Bio-Rad Laboratories Inc, Hercules, CA, USA) at
415 nm in 5-min intervals for 30 min. The maximum
slope over a 10-min period was used for analysis. All
samples were normalized to the average slope of the
saline-treated group for direct comparison.
Nitric oxide was measured using the colorimetric nitric
oxide assay Kit (ab65328; Abcam®, Cambridge, UK) that
uses Griess reagents to convert nitrite to a deep purple
azo compound. Mouse hemi-brain tissue was homoge-
nized in cold phosphate buffer 0.1 M (pH 8.0; 4 μl/mg
tissue) and protein content measured by the Bradford
assay (Bio-Rad Laboratories Inc, Hercules, CA, USA).
Brain samples (60 μg protein) were run in duplicates as
directed in the kit, and the absorbance was read at 540 nm
using a spectrophotometer (Bio-Rad Laboratories Inc,
Hercules, CA, USA).Statistics
The data are expressed as mean ± SEM. Statistical signifi-
cance was assessed using paired or unpaired t-tests or a
two-way analysis of variance followed by a Scheffé’s mul-
tiple comparison method (OpenStat software). Significance
was determined when P < 0.05.
Results
Cortical paired-pulse suppression is dependent on
inhibitory GABAA activity
Perfusate application of the GABAA inhibitor bicuculline
to cortical slices enables rapid evaluation of spontaneous
and evoked inhibitory activity. To assess inhibitory
involvement in cortical circuits, we used a paired-pulse
paradigm to assess evoked field postsynaptic potentials
(fPSP) in layer II/III of hindlimb/forelimb somatosensory
cortex (Figure 1A). Although we evoke both field poten-
tials, the first potential is essentially devoid of evoked
inhibitory input as inhibitory interneurons are recruited
with the first pulse to have impact on the second poten-
tial only. Thus, the first pulse of the pair represents
spontaneous activity (background inhibition) only,
whereas the ratio represents evoked inhibition. Two
stimulations (50 ms apart) of layer IV/V with a concentric
bipolar electrode typically showed 20% to 40% suppression
of the second fPSP that could be abolished by washing the
GABAA antagonist bicuculline (2 μM) over the slice in the
perfusate (Figure 1B,C,D). This bicuculline-sensitive com-
ponent of the paired-pulse ratio (Figure 1D), thus, can
serve as an indication of the magnitude of cortical evoked
inhibition. The corresponding increase in fPSP amplitude
with the addition of bicuculline to the perfusate can, like-
wise, be used as an indication of the level of spontaneous
inhibition in the acutely isolated brain slices used in this
study (Figure 1E).
Neuromodulators differentially affect cortical paired-pulse
suppression
In these studies, we used a novel and simple combination
of local bolus neuromodulator application, GABAA
pharmacology and recordings of paired-pulse extracellular
fPSPs to evaluate the temporal profiles of ACh, NE and 5-
HT effects on inhibitory and excitatory cortical network
components. Although all three neuromodulators reduce
the amplitude of the first pulse (49.9 ± 4.97% for ACh;
34.6 ± 5.75% for NE; 34.1 ± 7.04% for 5-HT, Figure 2A),
only 5-HT and NE effects appear to be sensitive to the
GABAA antagonist bicuculline (Figure 2A). We did not
observe a bicuculline effect on the ACh-mediated reduc-
tion in the first pulse amplitude of the paired-pulse regi-
men. Serotonin showed the most pronounced dependence
on GABA networks in the short term with a much slower
GABAA-independent suppression developing even after
washout (Figure 2A, bottom left).
Figure 2 Neuromodulators recruit different mechanisms to achieve their effects. (A) Time series recordings (every 20 s) of P1 and P2
amplitude responses to select neuromodulators before and after perfusion with bicuculline for assessment of effects on spontaneous and evoked
inhibition. (B) Time series recording of P2/P1 ratio before and after bicuculline perfusion for assessment of inhibition on frequency-dependent
transmission. Amplitudes or ratios were normalized to the average of ten traces immediately preceding neuromodulator application to enable
comparison. *P < 0.05, paired t-test. 5-HT, serotonin (N = 5 slices from five mice); ACh, acetylcholine (N = 6 slices from five animals); NE, norepinephrine
(N = 7 slices from four animals); min, minutes; P1, pulse 1; P2, pulse 2.
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effects on the second pulse, whereas NE-mediated suppres-
sion of P2 is significantly reduced following treatment with
bicuculline (Figure 2A, right). Assessment of the normal-
ized paired-pulse ratio with and without bicuculline in the
perfusate illustrates the dependence of GABAA receptors in
the neuromodulator effects on frequency transmission in
cortical networks (Figure 2B). Note that effects of 5-HT on
the paired-pulse ratio (frequency transmission) are com-
pletely blocked by inhibition of GABAA receptors whereas
the effects on ACh and NE are more subtle.
Systemic LPS induces transient behavioural changes and
an increase in nitric oxide production
Verification that systemic LPS had a behavioural effect
on the mice was accomplished by performing the tail
suspension test (a simple behavioural test of despair) in
separate cohorts of animals 1 day (N = 10 per group)
and 7 days (n = 8 per group) after systemic LPS adminis-
tration. Animals were assessed for total immobility and
latency to first immobility during 6 min of tail suspen-
sion. Latency to first immobility was significantly lower
in LPS-treated animals 1 day after LPS but not 7 days
after (Figure 3A, left). Interestingly, no difference wasobserved in total immobility at either day after LPS
treatment (Figure 3A, right).
As the inducible form of nitric oxide synthase (iNOS)
is intimately involved in the immune inflammatory
response [30,31], we also performed a simple assay for
levels of nitrates/nitrites in brain homogenates as a
measure of nitric oxide production (NO rapidly oxidized
to nitrite and nitrate). Despite not seeing any effect in the
tail suspension test at 7 days post LPS, the nitric oxide
assay showed a sixfold increase in nitric oxide production
in LPS-treated animals compared to saline-treated
controls (Figure 3B), indicative of a neuroinflammatory
effect.
Systemic LPS reduces both cortical inhibition and
neuromodulation
Perfusion of the tissue slice with the GABAA antagonist
bicuculline while monitoring the extracellular fPSPs
(0.33 Hz) demonstrates a loss of the GABAA-dependent
effects on P1 and P2 in slices from animals pretreated
with a single LPS injection 1 week earlier. The average
of five paired-pulse recordings was collected from each
slice before and after perfusion with bicuculline for
comparison of ratios and bicuculline-sensitive changes
Figure 3 Systemic LPS induces transient effects in the tail suspension test and an increase in nitric oxide production. (A) Histograms
comparing the latency to the first immobility and total immobility time at 1 day (N = 10, *P < 0.05, unpaired t-test) versus 7 days (N = 8, unpaired
t-test) post LPS treatment. (B) Histogram showing nitrate/nitrite levels of hemi-brain homogenates collected 7 days post LPS treatment (N = 9 per
group; *P < 0.001, unpaired t-test) LPS, lipopolysaccharide.
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treatment was significantly larger than that of the con-
trol as well as showing a loss of bicuculline sensitivity
(Figure 4A). Likewise, whereas P1 amplitude showed a
significant increase with bicuculline in control slices,
LPS-treated slices showed no P1 amplitude increase in
response to bicuculline addition (Figure 4B). Thus, LPS
treatment significantly reduces both spontaneous (P1)
and evoked (ratio) inhibition.
In addition to effects on cortical inhibition, systemic
injection of LPS also results in an altered neuromodula-
tor effect on cortical networks. Experiments were per-
formed with two different bolus concentrations each of
ACh, NE and 5-HT to ensure we were getting adequate
action on the various receptor subtypes (neuromodulator
bolus is diluted substantially before reaching the recording
site deep in the slice) (Figure 5). Initial experiments withFigure 4 LPS reduces both spontaneous and evoked cortical inhibitio
ratios (*P< 0.05, Scheffé’s multiple comparison). (B) Comparison of the bicucullin
groups (N= 18 slices from five animals in each group; *P< 0.001, paired t-test). Lthe higher neuromodulator concentrations demonstrated
a significant LPS-induced change in the temporal recovery
of the neuromodulator effects on the first pulse of the
paired-pulse regimen (Figure 5A, right) with minor effects
on the second pulse only seen with ACh (Figure 5A,
right). Subsequent use of lower neuromodulator concen-
trations was unable to replicate the LPS-mediated changes
to neuromodulator actions (Figure 5A, left). Additional
lowering of neuromodulator concentrations resulted in
many recordings not showing a neuromodulator response
(data not shown). Combined, these results demonstrate a
significant neuromodulator concentration-dependent
effect on the temporal neuromodulator recovery dynamics
with LPS treatment (two-way ANOVA; Figure 5B). A sig-
nificant increase in recovery of the neuromodulator effect
is seen in LPS-treated animals for all neuromodulators
examined (Figure 5B, high concentration).n. (A) Histograms comparing the bicuculline sensitivity of the paired-pulse
e sensitivity of the first pulse amplitude between saline- and LPS-treated
PS, lipopolysaccharide; P1, pulse 1; P2, pulse 2.
Figure 5 LPS alters neuromodulator action on cortical networks. (A) Low and high concentrations of bolus neuromodulator application
demonstrate an LPS-mediated concentration-dependent increase in the rate of response recovery. (Minimum of 24 slices from eight animals in
each group; *P < 0.05, unpaired t-test) (B) Histograms comparing the normalized recovery of the first pulse as determined by the average of five
stimulations demarcated by the grey-shaded boxes in (A) (*P < 0.05, Scheffé’s multiple comparison) ACh, acetylcholine; NE, norepinephrine; 5-HT,
serotonin; LPS, lipopolysaccharide; P1, pulse 1; P2, pulse 2.
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dependent on increased monoamine oxidase-A and
acetylcholinesterase activity
Altered neuromodulation in LPS-treated brain slices is
not due to an indirect reduction in inhibition. As we
saw above, LPS treatment leads to a significant loss of
both spontaneous and evoked inhibitory components
(Figure 4). Given that neuromodulator effects are known
to involve GABAA-mediated inhibition (Figure 2), we
compared the bicuculline-sensitive component of the
neuromodulator responses under saline or LPS pretreat-
ment conditions (Figure 6). Each slice was administered,
the neuromodulator twice, once before and once in the
presence of bicuculline in the perfusate (saline-treated
animals shown in Figure 2). To obtain the bicuculline-
sensitive component of the neuromodulator response,
we subtracted the response in bicuculline from the
response immediately before bicuculline application.
Although LPS-treated animals showed a small decrease
in the bicuculline-sensitive component of the early 5-HT
effect on the first pulse only, the bicuculline-sensitivecomponents of neuromodulation were basically unaffected
(Figure 6) suggesting that loss of inhibition in LPS-treated
brain slices does not account for the alteration observed in
neuromodulator effects.
To evaluate whether changes in MAO-A activity is re-
sponsible for the LPS-mediated changes in the temporal
profile of NE and 5-HT responses, we employed use of
the MAO-A inhibitor clorgyline. To adequately block
MAO-A activity in the perfused brain slice, slices were
incubated in aCSF-containing clorgyline (5 μM) for 1 to
2 h prior to experimental recordings. As opposed to the
reduced NE and 5-HT effects in LPS-treated slices in
the absence of MAO-A block (Figure 5), we found sig-
nificantly larger NE effects on pulse 1 and 5-HT effects
on both pulse 1 and 2 of the paired-pulse regimen in
slices from LPS-treated mice with no effect on ACh neu-
romodulation (Figure 7).
We next evaluated the role of ACh-E on LPS-mediated
changes in the temporal profile of ACh-mediated effects.
To assess the role of ACh-E in the reduced duration of
ACh effects in LPS-treated brain slices, we perfused the
Figure 6 Changes in GABAA-mediated inhibition do not
account for LPS-mediated changes in neuromodulator action.
Time series of the bicuculline-sensitive neuromodulator effects under
control and LPS pretreatment conditions is plotted for comparison.
Neuromodulator application in the presence of bicuculline (2 μm in
perfusate) was subtracted from the time series of neuromodulator
application before bicuculline administration (N = 5 slices from five
animals; *P < 0.05, unpaired t-test). 5-HT, serotonin; ACh, acetylcholine;
NE, norepinephrine; P1, pulse 1; P2, pulse 2; LPS, lipopolysaccharide.
Figure 7 Pharmacological inhibition of MAO-A shows increased
NE- and 5-HT-mediated effects on the paired-pulse regimen.
Time series plots of pulse 1 and 2 amplitudes in the presence of the
MAO-A inhibitor clorgyline illustrates an LPS-mediated enhancement
of NE and 5-HT effects without altering ACh-mediated effects. (N = 18
to 24 slices from five animals in each group; *P < 0.05, unpaired t-test).
5-HT, serotonin; ACh, acetylcholine; NE, norepinephrine;
LPS, lipopolysaccharide.
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like the effect of MAO-A inhibition on NE and 5-HT
responses in LPS-treated slices, ACh did not show en-
hanced amplitude responses in the presence of donepezil
(Figure 8A). Donepezil did, however, show a significant
treatment effect on the recovery of P1 amplitude to ACh
application (Figure 8B), supporting the notion of an in-
creased ACh-E activity in mediating the LPS effects on
ACh neuromodulation.
To further validate the role of MAO-A and ACh-E in
the corresponding changes of neuromodulator temporal
dynamics with LPS pretreatment, we assayed total MAO
activity and ACh-E activity in hemi-brain homogenates
from a subset of saline- (n = 14) and LPS- (n = 15) treated
mice. Both total MAO (saline 1.00 ± 0.028 vs LPS 1.15 ±
0.034%; P = 0.0016, unpaired t-test) and ACh-E (saline
1.00 ± 0.027 vs LPS 1.23 ± 0.043%; P = 0.0001, unpaired
t-test) activities were significantly increased in LPS-treated
mice.
Discussion
These studies use paired-pulse extracellular recordings
with GABAA pharmacology in superficial cortical layers
as a means of assessing inflammatory effects on both
inhibitory networks (Figure 1) and transient neuromo-
dulation (Figure 2) of cortical networks in adult brain
slices. Prior studies assessing neuromodulator effects
on synaptic activity administer the different neuromo-
dulators in the slice perfusate to allow the concentra-
tion to reach equilibrium throughout the tissue,
resembling tonic neuromodulator action associated
with general arousal and behavioural state. The present
study employs bolus application of the neuromodula-
tors upstream of the recording electrode in the slice
perfusate to more accurately simulate phasic release of
neuromodulators known to be associated with salient
environmental stimuli that are necessary for transient
modulation of executive functions. Few studies have
ever assessed neuromodulator function on network ac-
tivity in this way. Our results show that systemic LPS
injection not only reduces CNS inhibitory networks
(Figure 4) but also alters the temporal dynamics of neu-
romodulator activity (Figure 5) by increasing MAO-A
(Figure 7) and ACh-E (Figure 8) activity. It should be
noted that effects on temporal dynamics would not
have been observed had we been using bath perfusion
of the different neuromodulator concentrations or used
neuromodulator concentrations insufficient to saturate
local catabolic enzymes.
Neuromodulator effects on somatosensory cortical
networks
Using extracellular field recordings of a paired-pulse regi-
men, we were able to confirm some, but not all, of the
Figure 8 Pharmacological inhibition of ACh-E blocks LPS-mediated increases in recovery of ACh-mediated effects. (A) Time series plots
of normalized pulse 1 and 2 amplitudes in the absence and presence of the ACh-E inhibitor donepezil illustrating the loss of an LPS-mediated
enhancement in recovery of ACh-mediated effects (*P < 0.05, unpaired t-test). (B) Histograms comparing the normalized recovery of the first pulse
as determined by the average of five stimulations demarcated by the grey-shaded boxes in (A) (*P < 0.05, Scheffé’s multiple comparison) (N = 14
slices from five animals in saline group, N = 15 slices from four animals in LPS group). ACh, acetylcholine; con, control; aCSF, artificial cerebral
spinal fluid; don, donepezil; LPS, lipopolysaccharide; P1, pulse 1; P2, pulse 2.
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taneous and evoked inhibition in patch-clamped cortical
neurons.
In the bicuculline study of ACh, we were unable to un-
cover a GABAA-sensitive effect on either pulse 1 or 2
peak amplitude responses. This is directly in contrast
with patch-clamp studies of principal layer II neurons in
rat auditory [32] or entorhinal cortices [33], where they
found an ACh-mediated decrease in evoked and an in-
crease in spontaneous inhibition. As we observed very
similar changes in P1 and P2 amplitude using both low
and high concentrations, it is very possible that we were
using a saturating concentration where the direct effects
of ACh on cortical neurons overwhelms and/or masks
any bicuculline-sensitive component. Alternatively, the
low concentration of bicuculline used to avoid slice hy-
perexcitability may have only provided a fractional inhib-
ition of the GABAA-mediated component making it too
small to detect with extracellular field recordings.
Although no bicuculline sensitivity was observed on
peak ACh-mediated changes in amplitude, we found a
non-significant trend for slower and incomplete recovery
of pulse 1 amplitude in the presence of bicuculline. This
may be attributed to a bicuculline-mediated lowering of
the threshold for synapses to undergo cholinergic-
mediated long-term depression (LTD) [25]. Kirkwood et
al. [25] used a very similar paired-pulse model but with
bath application of neuromodulator for 10 min to induce
an LTD. In our study, bolus ACh application (transient
<1 min) did not induce LTD under baseline conditions.
However, with the increased excitability after addition of
bicuculline, it is possible that subsequent ACh applica-
tion might reach the threshold for LTD to occur.
Bicuculline-sensitive components of the NE effects on
pulse 1 and 2 are consistent with an increase in bothspontaneous and evoked inhibition, respectively. Reduction
of pulse 1 inhibition in the presence of bicuculline corre-
lates with an NE-mediated increase in spontaneous inhib-
ition, whereas the reduced pulse 2 inhibition in bicuculline
correlates with an NE-mediated increase in evoked inhib-
ition. This is consistent with the previously shown α1-
adrenergic receptor-mediated increase in frequency and
amplitude of spontaneous inhibitory postsynaptic currents
recorded (patch-clamp) from principal neurons in layer II/
III of rat entorhinal cortex [34] and a β- and α2-adrenergic
receptor-mediated increase in evoked inhibitory postsynap-
tic currents recorded from principal neurons in layer II/III
of rat auditory cortex [35,36]. Thus, in contrast to bicucul-
line studies with ACh, use of bicuculline pharmacology
does corroborate NE effects on inhibitory network activity
under the conditions used in these studies.
Studies assessing bicuculline sensitivity of 5-HT effects
on the paired-pulse regimen demonstrate a strong GABAA
component involved in the reduction of the first pulse
which is consistent with previous studies showing 5-HT1A
receptor involvement in 5-HT effects in rat entorhinal cor-
tex [37,38]. However, in contrast to the decrease in evoked
inhibition observed in a previous study in the entorhinal
cortex [38], we did not observe any impact on evoked in-
hibition. Lack of an observed effect on evoked inhibition
may be explained similarly to lack of responses seen with
ACh listed above. The slower onset of depression with
5-HT may suggest a role for GABAB receptors and/or an
effect on longer-term plasticity. In any case, 5-HT-
mediated shaping of cortical networks shows the greatest
dependence on recruitment of GABAA receptors.
Systemic LPS reduces cortical inhibition
The observed loss of spontaneous and evoked inhibition
in these studies supports an elevation of inflammatory
Ming et al. Journal of Neuroinflammation  (2015) 12:37 Page 10 of 11cytokines. Systemic LPS can increase inflammatory cyto-
kines IL-1β [6], IL-6 [7] and TNF-α [6] in the brain. The
measured increase in nitrates/nitrites as an indirect
measure of nitric oxide in response to LPS in these stud-
ies suggests an inflammatory-mediated increase in nitric
oxide synthase activity, supporting the probability of
increased inflammatory cytokine levels. As TNF-α has
been shown to cause internalization of GABAA receptors
[17] and IL-6 has been shown to reduce GABAA
receptor-mediated inhibition [14], the loss of cortical in-
hibition observed in these studies is consistent with an
LPS-mediated elevation in the neuroinflammatory state.
LPS-mediated effects on neuromodulation are dependent
on increased monoamine oxidase-A and acetylcholin-
esterase activity
Given that all three neuromodulators used in this study
have been shown to exert their neuromodulatory action
partially through changes in inhibitory GABAergic mecha-
nisms, it is possible that alteration in neuromodulator
function under inflammatory conditions could be due to
the loss of inhibitory network function. We found that
although all neuromodulators showed a concentration-
dependent increase in temporal recovery of responses,
only 5-HT showed some loss of the bicuculline-sensitive
neuromodulator effect in LPS-treated animal slices. This
strongly suggested that mechanisms other than loss of
inhibition are involved in the observed LPS-mediated
changes in neuromodulator function.
Use of selective MAO-A and ACh-E inhibitors as well as
activity measures from hemi-brain homogenates support
the notion that changes in enzyme activity in slices from
LPS-treated mice account for the altered temporal kinetics
of the observed neuromodulator actions. Use of the ACh-E
inhibitor donepezil, directly inhibited the significant in-
crease in ACh effect recovery observed in slices from LPS-
treated mice. MAO-A blockade results, however, proved
more complex. Given the fact that noradrenergic and sero-
tonergic receptor densities are adaptable to changes in the
environment, it is conceivable that receptor densities were
increased in LPS-treated mice to account for reduced NE
and 5-HT concentrations as a result of increased MAO-A
activity. Thus, the enhanced NE and 5-HT responses in
slices from LPS-treated mice in the presence of MAO-A
block may be indirect evidence of an enhanced MAO-A
activity. The observed effects of pharmacological inhibition
in slices is consistent with the observed increases in total
MAO and ACh-E activity found in LPS-treated brain
homogenates.
MAO-A expression has been widely shown to increase
in response to chronic stress [18] and glucocorticoids
[19,20] whereas ACh-E expression has been shown to in-
crease in response to IL-1 [22] as well as oxidative stress
[23,24]. Thus, similar to mechanisms for the loss of theobserved inhibition, increased MAO-A and ACh-E activity
are consistent with an increased inflammatory cytokine
expression in brain slices from mice pretreated with LPS.
Altered neuromodulator actions may be involved in the
cognitive and emotional aspects of LPS-mediated sickness
behaviour as well as provide a link to long-term neuro-
psychiatric and neurodegenerative disorders.Conclusions
These studies use a novel and simple extracellular record-
ing paradigm combined with bicuculline pharmacology and
transient bolus application of neuromodulators to evaluate
cortical inhibitory networks and neuromodulator-mediated
changes in integrated cortical network activity. We use this
model to show that LPS-mediated neuroinflammation
affects neuromodulation through effects on both cortical
inhibition and increases in MAO-A and ACh-E activity.
Although results only show an impact on the temporal
dynamics of neuromodulator action under conditions used
in these studies, it can be envisioned that an increase in
MAO-A and ACh-E activity will also reduce neuromodula-
tor action on a spatial scale. Thus, inflammatory-mediated
sickness behaviour may involve changes in inhibition as
well as loss of sensitivity to the different neuromodulators
known to be important in determining behavioural state.
Given the significant role of neuromodulators in behav-
ioural state and cognitive processes, it is possible that an
inflammatory-mediated change in neuromodulator action
plays a role in LPS-induced sickness behaviour and could
help define the link between infection and neuropsychi-
atric/degenerative conditions.Competing interests
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